Aminocamptothecin in Treating Patients With Recurrent or Unresectable Epithelial Ovarian Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of aminocamptothecin in treating patients
with recurrent or unresectable epithelial ovarian cancer that has been previously treated
with platinum-based chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health
Collaborators:
Eastern Cooperative Oncology Group National Cancer Institute (NCI)